Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes - PubMed
5 hours ago
- #renal therapy
- #diabetes management
- #cardiovascular health
- Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is studied for heart failure outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes.
- The research is based on pooled data from the FIDELIO-DKD and FIGARO-DKD trials, funded by Bayer AG, with independent academic analysis.
- Higher baseline heart failure risk correlates with greater absolute benefits from finerenone in preventing heart failure events.
- The study suggests finerenone's effectiveness increases in patients with elevated heart failure risk at baseline.
- Conflict of interest disclosures include multiple authors receiving funding, consulting fees, or employment ties with pharmaceutical companies, including Bayer.